Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZF1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,332
Award facts
- Contract value 100% obligated
- $19,332.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $19,332.22 to DMS Pharmaceutical Group Inc. on January 12, 2026, for the supply of Trikafta (elexacaftor/tezacaftor/ivacaftor) 100-50-75 mg/150 mg tablets. This delivery order operates under a firm fixed-price contract structure with an ultimate completion date of January 13, 2026 and represents a non-set-aside award. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as the prime contractor with no identified subcontractors. The product will be delivered to Park Ridge, Illinois, and the award carries no set-aside designation.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy. The parent IDC, valued at $499.999 billion with completion through December 31, 2036, authorizes the company to supply a comprehensive range of pharmaceutical products, including branded and generic prescription medications, biologics, and medical consumables to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group's established performance across numerous delivery orders demonstrates its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCZF1?
SPE2DR26FCZF1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FCZF1 worth?
The government has obligated $19,332 on SPE2DR26FCZF1.
Is contract SPE2DR26FCZF1 an order under another contract?
Yes. SPE2DR26FCZF1 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZF1 competed?
The extent of competition for SPE2DR26FCZF1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award